Hiddo J.L. Heerspink,Bergur V. Stefánsson,Ricardo Correa‐Rotter,Glenn M. Chertow,Tom Greene,Fan Fan Hou,Johannes F.E. Mann,John J.V. McMurray,Magnus Lindberg,Peter Rossing,C. David Sjöström,Roberto D. Toto,Anna-Maria Langkilde,David C. Wheeler
Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.